Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Total Current Liabilities (2018 - 2025)

Arcturus Therapeutics Holdings (ARCT) has disclosed Total Current Liabilities for 8 consecutive years, with $36.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Current Liabilities fell 44.45% year-over-year to $36.4 million, compared with a TTM value of $36.4 million through Dec 2025, down 44.45%, and an annual FY2025 reading of $36.4 million, down 44.45% over the prior year.
  • Total Current Liabilities was $36.4 million for Q4 2025 at Arcturus Therapeutics Holdings, up from $31.7 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $127.0 million in Q4 2022 and bottomed at $31.7 million in Q3 2025.
  • Average Total Current Liabilities over 5 years is $80.1 million, with a median of $84.8 million recorded in 2023.
  • The sharpest move saw Total Current Liabilities surged 322.07% in 2021, then crashed 57.2% in 2025.
  • Year by year, Total Current Liabilities stood at $99.5 million in 2021, then grew by 27.57% to $127.0 million in 2022, then plummeted by 35.43% to $82.0 million in 2023, then decreased by 20.12% to $65.5 million in 2024, then crashed by 44.45% to $36.4 million in 2025.
  • Business Quant data shows Total Current Liabilities for ARCT at $36.4 million in Q4 2025, $31.7 million in Q3 2025, and $46.5 million in Q2 2025.